Close

Drug Research

Shoreline Launches into Era of Cell Therapy with $4 Billion in Partnerships

Shoreline Biosciences, an immunotherapy company formed in 2020 during the early days of the COVID-19 pandemic, was propelled into the proverbial catbird’s seat this summer with two mega-deals, and now plans to double its employee base from 50 to...

Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets

Abveris, Inc., and Abilita Bio, Inc., both privately held biotechnology companies, announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment. The...

India’s first mRNA Covid vaccine by Gennova granted approval for Phase 2/3 clinical trails

India’s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trials, the Department of Biotechnology (DBT) said. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase...

Genevant Sciences Announces Global Collaboration with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company...

BMS obtains FDA approval for Opdivo as bladder cancer treatment

The US FDA has approved Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) as an adjuvant therapy for urothelial carcinoma (UC) patients at increased risk of recurrence following radical resection. A programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo can specifically harness the...

McMaster, Sartorius Enter Biomanufacturing Partnership

Sartorius Stedim Biotech, an international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers and genetic disorders. Using a state-of-the-art multi-column...

Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United States

Zydus Pharmaceuticals Inc, USA (a 100% subsidiary of Cadila Healthcare Limited (Zydus Cadila), a leading innovation-driven, global healthcare provider, has signed a license and supply agreement with CHEMI SpA (“CHEMI”) of Italy, a subsidiary of Italfarmaco Group, to launch...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read